Moreover, it has also shown effectiveness in combination with the histone deacetylase inhibitor vorinostat in NB harboring the ALK R1275Q mutation and after intensive radiotherapy for the treatment of a rare intraosseous RMS with FUS-TFCP2 fusion, evidencing the potential of this drug to treat extremely aggressive tumors [683,684]. The gene discussed is TFCP2; the disease is neuroblastoma.